10.1080/0886022X.2024.2441398 Summary Keywords gout, hyperuricemia, drug delivery systems, therapeutic, prospect Citation Peng Z, Meng F, Deng Q, Huang Y, Mao D, Long Y, Yan W, Peng J, Wang X and Liu N (2025) Advances in drug delivery systems for the management of gout and hyperuricemia
Disclosures: Keiko Iwaisako: Nothing to Disclose, Hiroaki Fuji: Nothing to Disclose, Momoko Fujita: Nothing to Disclose, Reina Sawabu: Nothing to Disclose, Shoko Tsukamoto: Nothing to Disclose, Masaki Yamamoto: Nothing to Disclose, Ryo Tofukuji: Nothing to Disclose, Masataka Asagiri: Nothing to Disclose, Daichi Nakamura: Nothing to Disclose, Keisuke Okura: Nothing to Disclose, Takahiro Nishio: Nothing to Disclose 1945 NRF2-MEDIATED IMMUNE COLD TUMOR MICROENVIRONMENT CONTRIBUTES TO RESISTANCE TO ATEZOLIZUMAB AND BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA Shuhei Yamamoto 1 Takahiro Kodama 1 Kazuki Maesaka 1 Akifumi Kuwano 2 kenta Motomura 2 Kumiko Shirai 1 Akira Doi 1 Kazuhiro Murai 1 Yuki Tahata 1 Yoshinobu Saito 3 Hayato Hikita 3 Tomohide Tatsumi 1 Tetsuo Takehara 1 , 1 Osaka University, 2 Iizuka Hospital, 3 Osaka University Graduate School of Medicine Background: Atezolizumab/ bevacizumab (Atezo/Bev) combination immunotherapy is the first-line treatment for advanced hepatocellular carcinoma (HCC), but around 20% of patients do not respond initially
The outdoor temperature determines how much time will be between each picking
Whether you're navigating a demanding routine, managing stress, or simply looking to maintain balanced nutrient levels, REVIVs B family injections are a popular option for individuals seeking to support their overall well-being as part of a proactive self-care approach
